TY - JOUR
T1 - Immunoprofiling toll-like receptor ligands
T2 - Comparison of immunostimulatory and proinflammatory profiles in ex vivo human blood models
AU - Hood, Jennifer D.
AU - Warshakoon, Hemamali J.
AU - Kimbrell, Matthew R.
AU - Shukla, Nikunj M.
AU - Malladi, Subbalakshmi S.
AU - Wang, Xinkun
AU - David, Sunil A.
N1 - Funding Information:
This work was supported in part by NIH/NIAID contract HHSN272200900033C, and the University of Kansas Start-up Funds. J.D.H. is grateful to the KU-PREP program for financial support.
PY - 2010/4
Y1 - 2010/4
N2 - There is a pressing need for the development of novel, safe and effective adjuvants. The recent discovery and characterization of pathogen-associated molecular pattern (PAMP)-recognizing elements such as the Toll-like, NOD-like and RIG-like receptors, has brought into sharp focus the role of PAMPs in bridging the innate and adaptive immune responses, and a detailed understanding of the immunostimulatory vis-à-vis proinflammatory activities could lead to the development of effective adjuvants, monophosphoryl lipid A being an excellent example. We describe in this paper a series of hierarchical assays that were employed to characterize TLR agonists in vitro including primary TLR-reporter assays, secondary indices of immune activation, and tertiary screens characterizing transcriptomal activation patterns to identify optimal immunostimulatory chemotypes. The evaluation of representative members of known human TLR agonists demonstrate that TLR2, -4, -5 and -7 agonists were immunostimulatory. TLR7 agonists were extremely immunostimulatory, stimulating nearly all subsets of lymphocytes without inducing proinflammatory cytokine responses. The TLR5 agonist, flagellin, while immunostimulatory, was also highly proinflammatory. These results suggest that TLR agonists other than lipid A-like chemotypes could be developed into potential adjuvants, and that this series of hierarchical assays could be adapted to rapidly identify in large libraries, compounds with adjuvantic potential that lack proinflammatory responses.
AB - There is a pressing need for the development of novel, safe and effective adjuvants. The recent discovery and characterization of pathogen-associated molecular pattern (PAMP)-recognizing elements such as the Toll-like, NOD-like and RIG-like receptors, has brought into sharp focus the role of PAMPs in bridging the innate and adaptive immune responses, and a detailed understanding of the immunostimulatory vis-à-vis proinflammatory activities could lead to the development of effective adjuvants, monophosphoryl lipid A being an excellent example. We describe in this paper a series of hierarchical assays that were employed to characterize TLR agonists in vitro including primary TLR-reporter assays, secondary indices of immune activation, and tertiary screens characterizing transcriptomal activation patterns to identify optimal immunostimulatory chemotypes. The evaluation of representative members of known human TLR agonists demonstrate that TLR2, -4, -5 and -7 agonists were immunostimulatory. TLR7 agonists were extremely immunostimulatory, stimulating nearly all subsets of lymphocytes without inducing proinflammatory cytokine responses. The TLR5 agonist, flagellin, while immunostimulatory, was also highly proinflammatory. These results suggest that TLR agonists other than lipid A-like chemotypes could be developed into potential adjuvants, and that this series of hierarchical assays could be adapted to rapidly identify in large libraries, compounds with adjuvantic potential that lack proinflammatory responses.
KW - Adjuvants
KW - Flagellin
KW - Imidazoquinoline
KW - Innate immunity
KW - Lipopeptides
KW - Lipopolysaccharide
KW - TLR
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=77953202237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953202237&partnerID=8YFLogxK
U2 - 10.4161/hv.6.4.10866
DO - 10.4161/hv.6.4.10866
M3 - Article
C2 - 20372068
AN - SCOPUS:77953202237
SN - 1554-8600
VL - 6
SP - 322
EP - 335
JO - Human vaccines
JF - Human vaccines
IS - 4
ER -